Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. OBJECTIVE: Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance prescribing efficiency before a decision to prescribe a particular medicine. Subsequently utilize the findings to suggest potential future initiatives that countries could consider. METHOD: An analysis of different methodologies involving cross national and single country retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries. RESULTS: Nature and intensity of the various initiatives appreciably influenced prescribing behavior and expenditure, e.g., multiple measures resulted in reimbursed expenditure for PPIs in Scotland in 2010 56% below 2001 levels despite a 3-fold increase in utilization and in the Netherlands, PPI expenditure fell by 58% in 2010 vs. 2000 despite a 3-fold increase in utilization. A similar picture was seen with prescribing restrictions, i.e., (i) more aggressive follow-up of prescribing restrictions for patented statins and ARBs resulted in a greater reduction in the utilization of patented statins in Austria vs. Norway and lower utilization of patented ARBs vs. generic ACEIs in Croatia than Austria. However, limited impact of restrictions on esomeprazole in Norway with the first prescription or recommendation in hospital where restrictions do not apply. Similar findings when generic losartan became available in Western Europe. CONCLUSIONS: Multiple demand-side measures are needed to influence prescribing patterns. When combined with supply-side measures, activities can realize appreciable savings. Health authorities cannot rely on a "spill over" effect between classes to affect changes in prescribing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weng, T.-C., Yang, Y.-H. K., Lin, S.-J., & Tai, S.-H. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01085.x · Cited by 345 · cited 1×
“…and renin-angiotensin inhibitor drugs, with the latter including angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) (Weng et al., 2010; Wettermark et al., 2010; Vonˇcina et al., 2011; Godman et al., 2012a, 2013a; Moon et al., 2010; Martin et al., 2014).”
Background
Cited by
Irrational Use of Medicines—A Summary of Key Concepts
Ofori-Asenso, R., & Agyeman, A. (2016) · Pharmacy · doi:10.3390/pharmacy4040035 · Cited by 287
Godman, B., Haque, M., McKimm, J., Abu Bakar, M., Sneddon, J., Wale, J., Campbell, S., Martin, A. P., Hoxha, I., Abilova, V., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1700947 · Cited by 171
Self-citationBochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00942 · Cited by 112
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationDisinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Parkinson, B., Sermet, C., Clement, F., Crausaz, S., Godman, B., Garner, S., Choudhury, M., Pearson, S.-A., Viney, R., Lopert, R., et al. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0293-8 · Cited by 93
Self-citation
Metadata
- Authors
- Godman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-Madrazo, S., Berg, C., Bishop, I., Bucsics, A., Campbell, S., Finlayson, A. E., Fürst, J., Garuoliene, K., Herholz, H., Kalaba, M., Laius, O., Piessnegger, J., Sermet, C., Schwabe, U., Vlahović-PalÄevski, V. V., Markovic-Pekovic, V., VonÄina, L., Malinowska, K., Zara, C., & Gustafsson, L. L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2014-06-17
- Volume
- 5
- Pages
- 106-106
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2111321650
- Cited by
- 128
- References
- 1
- FWCI
- 40.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.